Skip to contentB
Bone Biologics Corp
B
BBLGBone Biologics Corp Q4 2020 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$0.00$0.00derivedno prior Q4 2019 on file Net Income-$453.71K-$453.71KderivedN/M vs Q4 2019 EPS, diluted—Not derived. Share counts vary by quarter.
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Bone Biologics Corp · CIK 1419554 · Engraved from SEC EDGAR
Operating Incomederived-$206,432N/M Operating Cash Flowderived-$125,693N/M ended Dec 31, 2020 · filed Apr 15, 2021 · 105 d after period end